

1       Theodore A. Griffinger, Jr. (SBN 66028)  
2       Tanya Herrera (SBN 177790)  
3       STEIN & LUBIN LLP  
4       Transamerica Pyramid  
5       600 Montgomery Street, 14th Floor  
6       San Francisco, CA 94111  
7       Telephone: (415) 981-0550  
8       Facsimile: (415) 981-4343  
9       tgriffinger@steinlubin.com  
10      therrera@steinlubin.com

John S. Claassen (SBN 212954)  
CLAASSEN, Professional Corporation  
1970 Broadway, Suite 525  
Oakland, CA 94612  
Tel: (510) 251-8010  
Fax: (510) 868-3398

Attorneys for Defendants  
Brian Campion, Notebookz, Inc., &  
Joshua Rosen

7 Attorneys for Defendants,  
JON SABES, STEVEN SABES AND  
MARVIN SIEGEL

8 Tom Chia-Kai Wang (SBN 269050)  
9 THE LAW OFFICES OF TOM CHIA-KAI  
10 WANG  
11 117 West 9th St., Suite 206  
Los Angeles, CA 90015  
Tel: (213) 290-0930  
Fax: (213) 210-2192

Mary C. Garfein (SBN 195923)  
2469 Warren Lane  
Walnut Creek, CA 94597  
Tel.: (925) 788-8320

Attorneys for Defendant  
Jorge Fernandes

12  
13 Attorneys for Defendant  
Mani Kulasooriya

18 Attorneys for Defendant  
Steve Waterhouse

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA  
OAKLAND DIVISION

23 || SUZANNE D. JACKSON.

Case No. 4:11-cv-02753-PJH

24 Plaintiff,

25

26 WILLIAM FISCHER; JON SABES;  
27 STEVEN SABES; MARVIN SIEGEL;  
28 BRIAN CAMPION; LONNIE  
BROOKBINDER; MANI  
KOOLASURIYA, JORGE FERNANDES,

**DEFENDANTS' NOTICE OF MOTION  
AND CONSOLIDATED MOTION FOR  
JUDGMENT ON THE PLEADINGS**

Date: N/A  
Time: N/A  
Dept: Courtroom 3, 3<sup>rd</sup> Fl.  
Judge: Honorable Phyllis J. Hamilton

1 JOSHUA ROSEN, STEVE  
2 WATERHOUSE, JEAN PAUL a/k/a  
3 "BUZZY" LAMERE, UPPER ORBIT,  
4 LLC, SPECIGEN, INC.; PEER DREAMS  
5 INC.; NOTEBOOKZ INC.;  
6 ILEONARDO.COM INC.; NEW MOON  
7 LLC; MONVIA LLC, CII LIMITED; and  
8 SAZANI BEACH HOTEL,

9  
10 Defendants.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

1

## TABLE OF CONTENTS

	Page
I. INTRODUCTION .....	1
II. SUMMARY OF ALLEGATIONS .....	1
A. Allegations Regarding SpeciGen .....	2
B. Allegations Regarding "Notebookz/iLeonardo" .....	3
C. Allegations Regarding PeerDreams .....	5
III. PROCEDURAL BACKGROUND .....	6
IV. APPLICABLE LEGAL STANDARDS .....	8
V. ARGUMENT .....	9
A. Plaintiff Fails To Allege A Primary Violation Of Section 10(b) .....	9
1. Plaintiff Fails To Allege An Actionable Misstatement By Mr. Fischer .....	10
a. Plaintiff Fails To Allege An Actionable Misstatement Regarding SpeciGen .....	10
b. Plaintiff Fails To Allege An Actionable Misstatement Regarding Notebookz .....	14
c. Plaintiff Fails To Allege An Actionable Misstatement Regarding PeerDreams .....	18
2. Plaintiff Fails To Allege Facts Raising An Inference That Mr. Fischer Acted With Scienter .....	20
B. Plaintiff Fails To Allege A Primary Violation Of Sections 25401 and 25501 .....	21
C. Plaintiff Fails To Allege A Primary Violation Of Section 25501.5 .....	22
1. Plaintiff's Section 25501.5 Claims Fail Because She Cannot Allege That She Purchased Securities From Mr. Fischer .....	23
2. Plaintiff's Section 25501.5 Claim Is Time-Barred .....	24
VI. CONCLUSION .....	26

## TABLE OF AUTHORITIES

## FEDERAL CASES

4	<i>Ashcroft v. Iqbal</i> 556 U.S. 662 (2009) .....	8
5		
6	<i>Binder v. Gillespie</i> 184 F.3d 1059 (9th Cir. 1999) .....	9
7		
8	<i>Cafasso, U.S. ex rel. v. General Dynamics C4 Systems, Inc.</i> , 637 F.3d 1047 (9 <sup>th</sup> Cir. 2011) .....	8
9		
10	<i>Chavez v. U.S.</i> 683 F.3d 1102 (9 <sup>th</sup> Cir. 2012) .....	8
11		
12	<i>Copperstone v. TCSI Corp.</i> 1999 WL 33295869 (N.D. Cal. Jan. 19, 1999) .....	11
13		
14	<i>Falkowski v. Imation Corp.</i> 309 F.3d 1123 (9 <sup>th</sup> Cir. 2002) .....	11
15		
16	<i>Harris v. County of Orange</i> 682 F.3d 1126 (9 <sup>th</sup> Cir. 2012) .....	8
17		
18	<i>Hopkins v. Dow Corning Corp.</i> 33 F.3d 1116 (9 <sup>th</sup> Cir. 1994) .....	25
19		
20	<i>In re Bare Escentuals, Inc. Sec. Litig.</i> 745 F.Supp.2d 1052 (N.D. Cal. 2010) .....	9
21		
22	<i>In re Oracle Corp. Sec. Litig.</i> 627 F.3d 376 (9 <sup>th</sup> Cir. 2010) .....	14
23		
24	<i>In re Rigel Pharmaceuticals, Inc. Sec. Litig.</i> 697 F.3d 869 (9 <sup>th</sup> Cir. 2012) .....	21
25		
26	<i>In re Silicon Graphics, Inc.</i> 183 F.3d 970 (9 <sup>th</sup> Cir. 1999) .....	10, 20
27		
28	<i>In re Syntex Corp. Sec. Litig.</i> 95 F.3d 922 (9 <sup>th</sup> Cir. 1996) .....	14
29		
30	<i>In re Vantive Corp. Sec. Litig.</i> 283 F.3d 1079 (9 <sup>th</sup> Cir. 2002) .....	12, 13, 14, 21
31		
32	<i>In re VeriFone Holdings, Inc. Sec. Litig.</i> 704 F.3d 694 (9 <sup>th</sup> Cir. 2012) .....	20
33		

1	<i>In re VeriFone Sec. Litig.</i>	
2	784 F.Supp. 1471 (N.D. Cal. 1992), <i>aff'd</i> 11 F.3d 865 (9 <sup>th</sup> Cir. 1993).....	11
3	<i>Jackson v. Fischer</i>	
4	931 F.Supp.2d 1049 (N.D. Cal. 2013) .....	10, 22, 24, 25
5	<i>Kramas v. Security Gas &amp; Oil, Inc.</i>	
6	672 F.2d 766 (9 <sup>th</sup> Cir. 1982).....	25
7	<i>Matrixx Initiatives, Inc. v. Siracusano</i>	
8	____ U.S. ___, 131 S.Ct. 1309 (2011) .....	20
9	<i>Metzler Investment GmBH v. Corinthian Colleges, Inc.</i>	
10	540 F.3d 1049 (9 <sup>th</sup> Cir. 2008).....	12
11	<i>Micrel, Inc. v . Monolithic Power Systems, Inc.</i>	
12	2005 WL 6426678 (N.D. Cal. Dec. 9, 2005) .....	25
13	<i>No. 84 Employer-Teamster Joint Council Pension Trust Fund v. Am. W. Holding Corp.</i>	
14	320 F.3d 920 (9 <sup>th</sup> Cir. 2003).....	14
15	<i>Plumbers &amp; Pipefitters Local 572 Pension Fund v. Cisco Systems, Inc.</i>	
16	411 F.Supp.2d 1172 (N.D. Cal. 2005) .....	8
17	<i>Swartz v. KPMG LLP</i>	
18	476 F.3d 756 (9 <sup>th</sup> Cir. 2007).....	9
19	<i>Tellabs, Inc. v. Makor Issues &amp; Rights, Ltd.</i>	
20	551 U.S. 308, 127 S.Ct. 2499 .....	20
21	<i>Verona Partners, LLC v. Tenet Capital Partners Convertible Opportunities Fund, L.P.</i>	
22	2006 WL 2669035 (N.D. Cal., Sept. 18, 2006) .....	21
23	<i>Vess v. Ciba Geigy Corp. USA</i>	
24	317 F.3d 1097 (9 <sup>th</sup> Cir. 2003).....	9
25	<i>Wenger v. Lumisys, Inc.</i>	
26	2 F.Supp.2d 1231 (N.D. Cal. 1998) .....	10, 11
27	<i>Zucco Partners, LLC v. Digimarc Corp.</i>	
28	552 F.3d 981 (9 <sup>th</sup> Cir. 2009).....	10
29	<b>CALIFORNIA CASES</b>	
30	<i>Alpinieri v. TGG Management Company</i>	
31	2014 WL 1761327 (Cal.App. 4 Dist. May 5, 2014) .....	23, 24
32	<i>Apollo Capital Fund LLC v. Roth Capital Partners, LLC</i>	
33	158 Cal.App.4 <sup>th</sup> 226 (2007).....	22

1	<i>Bowden v. Robinson</i> 67 Cal.App.3d 705 (1977).....	22
2		
3	<i>Deveny v. Entropin, Inc.</i> 139 Cal.App.4 <sup>th</sup> 408 (2006) .....	25
4		
5	<i>Mirkin v. Wasserman</i> 5 Cal.4 <sup>th</sup> 1082 (1993) .....	23
6		
7	<i>Viking Pools, Inc. v. Maloney</i> 48 Cal.3d 602 (1989) .....	23
8		
9	<b>FEDERAL STATUTES</b>	
10	11 U.S.C. § 362(a)(1).....	6
11		
12	Private Securities Litigation Reform Act of 1995	
13	15 U.S.C. § 78u-4(b)(2).....	20, 21
14	15 U.S.C. § 78u-4(b)(1) .....	10
15	15 U.S.C. § 78u-4(b)(3)(A).....	10
16		
17	Securities Act of 1934	
18	15 U.S.C. § 78j(b) .....	9
19		
20	<b>RULES &amp; REGULATIONS</b>	
21	Rule 12(b)(6).....	8
22		
23	Rule 12(c).....	8
24		
25	<b>FEDERAL RULES OF CIVIL PROCEDURE</b>	
26		
27	F.R.C.P.	
28	§ 9(b) .....	9, 10, 11, 22
29		
30	<b>CALIFORNIA STATUTES</b>	
31		
32	Cal. Corp. Code	
33	§ 25004.....	24
34	§ 25401 .....	21, 22
35	§ 25500.....	23
36	§ 25501 .....	passim
37	§ 25506.....	24, 25
38		
39	California Civil Code § 338(a).....	24
40		
41	<b>OTHER AUTHORITIES</b>	
42		
43	Regulation D, 17 C.F.R. §§ 230.501-230.508	
44	Rule 10b-5.....	9
45		

## **NOTICE OF MOTION AND MOTION**

**TO PLAINTIFF AND HER COUNSEL OF RECORD:**

15 Defendants make this motion pursuant to Federal Rules of Civil Procedure 12(c), 9(b) and  
16 8(a) on the grounds that:

17       1. Plaintiff's First Claim for Relief for violations of Section 10(b) of the Securities  
18 Exchange Act of 1934, 15 U.S.C. § 78j(b) ("Section 10(b)") fails to state a primary violation  
19 against Mr. Fischer because (a) the TAC fails to specify the statement or statements alleged to  
20 have been false or misleading with the specificity required by Rule 9(b) and the Private Securities  
21 Litigation Reform Act of 1995, 15 U.S.C. § 78u-4 (the "PSLRA"); (b) the TAC fails to identify a  
22 material misstatement; (c) the TAC fails to plead facts establishing that any misstatement was  
23 false or misleading when made; and (d) the TAC fails to plead facts giving rise to a strong  
24 inference of scienter.

25        2. Plaintiff's Second Claim for Relief for violations of California Corporations Code  
26        Sections 25401 and 25501 ("Sections 25401and 25501") fails to state a primary violation against

<sup>27</sup> 1 Defendants' motion will be decided on the papers pursuant to the Court's minute order dated  
28 April 10, 2014. ECF No. 250.

1 Mr. Fischer because (a) the TAC fails to allege that Mr. Fischer made statement that was false or  
2 misleading with the specificity required by Rule 9(b); and (b) the TAC fails to allege that Mr.  
3 Fischer was an actual seller of securities, as required by Sections 25401 and 25501;

4       7. Plaintiff's Ninth Claim for Relief for violations of California Corporations Code  
5 Section 25501.5 ("Section 25501.5") fails to state a primary violation against Mr. Fischer because  
6 (a) the TAC fails to allege that Plaintiff purchased securities from Mr. Fischer; and (b) Plaintiff's  
7 claim for relief under Section 25501.5 is time-barred;

8       Defendants' motion is based on this Notice of Motion and Motion, the accompanying  
9 Memorandum of Points and Authorities, Requests for Judicial Notice and Declarations of Tanya  
10 Herrera, Joshua Rosen and Mani Kulasooriya, filed and served herewith, the pleadings and  
11 records on file herein, and such additional materials as may be presented to the Court in  
12 connection with Defendants' motion.

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

1       **I.       INTRODUCTION**

2           Plaintiff commenced this action almost three years ago. From the beginning, Plaintiff has  
 3 focused on alleged wrongdoing by Mr. Fischer. Indeed, Plaintiff's Secondary Liability Claims –  
 4 which are the only remaining claims against most of the Defendants – depend upon the existence  
 5 of a primary violation by Mr. Fischer. But despite Mr. Fischer's central role in this case, Plaintiff  
 6 has never alleged a viable claim for relief against him.

7           Although the Court has previously entertained several motions to dismiss, the Court has  
 8 not had an opportunity to consider Plaintiff's allegations against Mr. Fischer until now. As  
 9 discussed in detail below, the TAC fails to state a claim for relief against Mr. Fischer under any  
 10 theory. Accordingly, Plaintiff's Secondary Liability Claims against Defendants also fail.  
 11 Defendants' motion for judgment on the pleadings should be granted and Plaintiff's Secondary  
 12 Liability Claims should be dismissed without further leave to amend.

13       **II.       SUMMARY OF ALLEGATIONS<sup>2</sup>**

14           The TAC alleges that Plaintiff was the victim of a scheme to defraud orchestrated by Mr.  
 15 Fischer. Plaintiff met Mr. Fischer in October 2006. TAC at ¶ 34. According to Plaintiff, Mr. Fischer  
 16 presented himself as a "sophisticated investment advisor" with "connections to high tech issuers" and  
 17 "access to early investment opportunities." *Id.* at ¶ 38. In reality, Plaintiff contends, Mr. Fischer  
 18 misrepresented his background and experience as an investor in order to take advantage of her newly  
 19 acquired interest in investing. *Id.* at ¶¶ 35-36. In addition, Plaintiff claims that Mr. Fischer  
 20 fraudulently induced her to lend money or invest in a number of different entities, including  
 21 SpeciGen, Inc. ("SpeciGen"), PeerDreams, Inc. ("PeerDreams"), Notebookz, Inc. ("Notebookz") and  
 22 iLeonardo.com, Inc. ("iLeonardo") (together, the "Defendant Companies"), by misrepresenting their  
 23 prospects for success.<sup>3</sup> *Id.* at ¶¶ 78-113. Plaintiff's allegations with respect to each of the Defendant

---

25           <sup>2</sup> Plaintiff's allegations are accepted as true for purposes of this motion only.

26           <sup>3</sup> The SpeciGen Defendants are alleged to have been officers and/or directors of SpeciGen.  
 27 TAC at ¶¶ 8-11. The PeerDreams Defendants are alleged to have been directors of PeerDreams  
 28 (TAC at ¶¶ 13-14) and the Notebookz Defendants are alleged to have been officers and/or directors of  
 Notebookz. *Id.* at ¶¶ 15-16. Mr. Rosen (who is alleged to have been a founder, chief executive  
 officer and director of Notebookz) is also alleged to have been a founder, chief executive officer and

1 Companies are summarized below.

2           **A.     Allegations Regarding SpeciGen**

3 Plaintiff alleges that she made a series of loans to SpeciGen in the form of convertible  
 4 promissory notes between December 1, 2006 and sometime in “the summer of 2008.” TAC at ¶ 86.  
 5 Plaintiff does not say whether she purchased convertible promissory notes from Mr. Fischer,  
 6 SpeciGen or some other person or entity. *Id.* However, the judicially noticeable Note and Warrant  
 7 Purchase Agreement between Plaintiff and SpeciGen (the “SpeciGen Agreement”) confirms that she  
 8 purchased convertible promissory notes from SpeciGen, not Mr. Fischer.<sup>4</sup> Thus, Plaintiff does not –  
 9 and cannot – allege that she purchased SpeciGen securities from an unlicensed broker-dealer. *See*  
 10 Section V.C.1, *infra*.<sup>5</sup>

11 Plaintiff alleges that Mr. Fischer orally misrepresented SpeciGen’s fundraising and product  
 12 development efforts during “multiple meetings” in “October and November 2006.” *Id.* at ¶ 87.  
 13 According to the TAC, Mr. Fischer falsely represented that:

- 14           • SpeciGen’s technology was a “proven concept” (TAC at ¶ 87(a));
- 15           • SpeciGen’s technology was being reviewed for partnering or licensing by one or more  
 16           unidentified “publicly traded pharmaceutical companies” (*id.*);
- 17           • SpeciGen had an “industrial research collaboration” with an unidentified “prominent  
 18           biotech company” (*id.* at ¶ 87(c));
- 19           • SpeciGen’s technology had been “validated” by an unidentified “commercial biotech  
 20           company” (*id.* at ¶ 87(d));
- 21           • SpeciGen “had all of the licenses and patents needed to commercially develop its  
 22           technologies” (*id.* at ¶ 87(h));

---

23           director of iLeonardo. *Id.* at ¶ 15. With the exception of Mr. Fischer, none of the other individual  
 24           defendants are alleged to have been involved with iLeonardo.

25           <sup>4</sup> A true and correct copy of the SpeciGen Agreement is attached to the previously filed  
 26           Declaration of William Fischer (“Fischer Decl.”), a true and correct copy of which is attached to the  
 27           accompanying Declaration of Tanya Herrera (“Herrera Decl.”) as Exhibit (“Ex.”) A. *See also*  
 28           Defendants’ Request for Judicial Notice (“RJN”), filed and served herewith.

5 As discussed in detail below, Section 25501.5 does not apply to issuers. *See* Section V.C,  
 29           *infra*.

- 1     • SpeciGen's Series A offering "would be fully sufficient to carry the company to its  
2     ‘exit strategy,’ at which point [Plaintiff] could recover her investment at a profit" (*id.*  
3     at ¶ 87(b));
- 4     • SpeciGen's "exit strategy" would come within two or three years (*id.* at ¶ 87(g));
- 5     • SpeciGen's Series A offering "consisted solely of convertible promissory notes" (*id.*  
6     at ¶ 87(e)); and
- 7     • SpeciGen's Series A offering "was fully subscribed" by "sophisticated investors with  
   biotech startup knowledge and experience" (*id.* at ¶ 87(f)).

8 Plaintiff also alleges that Mr. Fischer orally misrepresented SpeciGen's fundraising and  
9 partnership prospects during a dinner meeting in Palo Alto in February 2007. TAC at ¶¶ 88-89.  
10 According to the TAC, Mr. Fischer falsely represented that:

- 11     • SpeciGen's Series A offering "was moving along well" (TAC at ¶ 89(a));
- 12     • "Genentech had vetted the company's technology" (*id.* at ¶ 89(b)); and
- 13     • SpeciGen was "in advanced discussions" with an unidentified "public company and  
14     an established private biotech company about advanced research partnerships that  
15     would develop preclinical data sufficient to complete clinical trials" (*id.* at ¶ 89(c)).

16 Plaintiff does not allege that Mr. Fischer – or anyone else connected to SpeciGen – made any  
17 misstatement of material fact in writing. Nor does Plaintiff specify what Mr. Fischer actually said  
18 about SpeciGen, why the statements were allegedly false or misleading when made or the factual  
19 basis for a strong inference that they were made with scienter. As discussed in detail below, these  
20 pleading failures are fatal to Plaintiff's attempt to plead a Section 10(b) claim against Mr. Fischer  
21 based on any alleged misrepresentation regarding SpeciGen. *See* Section V.A, *infra*.

22     **B.     Allegations Regarding "Notebookz/iLeonardo**

23     Next, the TAC alleges that Plaintiff made two loans to "Notebookz/iLeonardo" in the form  
24 of convertible promissory notes in February and April 2007. TAC at ¶ 94. Once again, Plaintiff  
25 does not say whether she purchased convertible promissory notes from Mr. Fischer or someone  
26 else. *Id.* However, the judicially noticeable Series A Preferred Stock Purchase Agreement  
27 between Plaintiff and Notebookz (the "Notebookz Agreement") confirms that she purchased  
28

1 preferred shares from Notebookz, not Mr. Fischer.<sup>6</sup> Thus, Plaintiff cannot plausibly allege that  
 2 she purchased Notebookz securities from an unlicensed broker-dealer. *See Section V,C,1, infra.*

3 The TAC alleges that Mr. Fischer fraudulently induced the loans by means of a series of  
 4 oral misstatements alleged to have been made during meetings in February and March 2007.  
 5 TAC at ¶¶ 94-95. Although Notebookz and iLeonardo are alleged to have been two separate  
 6 companies (*id.* at ¶¶ 21-22), Plaintiff repeatedly refers to them as “the company,” leaving  
 7 Defendants to guess which “company” she means. For example, Plaintiff alleges that Mr. Fischer  
 8 and/or Mr. Rosen falsely represented that “they expected Google to acquire the company” (*id.* at ¶  
 9 97(b)), without making any attempt to specify *which* speaker or *which* company.<sup>7</sup> Similarly,  
 10 Plaintiff alleges that Mr. Fischer falsely represented that:

- 11     • “the company had, independently of [Plaintiff’s] investment, raised sufficient  
 12        capital to produce and market its product” (TAC at ¶ 97(a));
- 13     • “the company had ‘discussed with [Plaintiff] the company’s business,  
 14        management, financial affairs’ and the details of its offering” (*id.* at ¶ 97(b));<sup>8</sup>
- 15     • “the company had given [Plaintiff] the opportunity to review the company’s  
 16        facilities” (*id.* at ¶ 97(c)); and
- 17     • “the company had given [Plaintiff] the opportunity to review all of the terms and  
 18        conditions of its securities offering (*id.* at ¶ 97(d)).

19 The TAC does not explain why any of the alleged misstatements were false or misleading when  
 20 made. Nor does the TAC explain how Plaintiff could have reasonably relied on alleged  
 21 misrepresentations regarding information within her own knowledge and experience (such as  
 22 whether or not she was given an opportunity to tour “the company’s facilities”).

23 Plaintiff also alleges that Mr. Fischer gave her an “Investor’s Rights Agreement” which  
 24 falsely represented that:

---

25     <sup>6</sup> A true and correct copy of the Notebookz Agreement is attached to the accompanying  
 26 Declaration of Joshua Rosen (“Rosen Decl.”) as Ex. 1.

27     <sup>7</sup> For ease of reference, and for purposes of this motion only, Defendants will assume that Mr.  
 28 Fischer, and only Mr. Fischer, made the alleged misstatements.

8 The TAC does not indicate what, if anything, Plaintiff is quoting.

- “The company . . . [would] . . . provide a balance sheet, statements of income and cash flows within 120 days of the end of each fiscal year . . .” (TAC at ¶ 98(a)); and
- “The company . . . would provide [Plaintiff] with unaudited statements of income and cash flows, an unaudited balance sheet and a statement of stockholders’ equity” within 45 days of the close of the third quarter of each year (*id.* at ¶ 98(b)).

Once again, Plaintiff does not specify *which* company allegedly promised to provide financial information, or why the promises were allegedly false or misleading when made. As discussed in detail below, these pleading failures are fatal to Plaintiff’s attempt to allege a primary violation of state or federal securities laws against Mr. Fischer. *See* Section V.A, *infra*.

### C. Allegations Regarding PeerDreams

Finally, Plaintiff alleges that she made a series of six loans to PeerDreams in the form of convertible promissory notes between January 2007 and June 2009. TAC at ¶ 103. The TAC does not specify whether Plaintiff purchased convertible promissory notes from Mr. Fischer or someone else. *Id.* However, the judicially noticeable Note and Warrant Purchase Agreements between Plaintiff and PeerDreams (the “PeerDreams Agreements”) confirm that she purchased convertible promissory notes from PeerDreams, not Mr. Fischer.<sup>9</sup> Thus, Plaintiff cannot plausibly allege that she purchased PeerDreams securities from an unlicensed broker-dealer. *See* Section V.C.1, *infra*.

Plaintiff alleges that Mr. Fischer misrepresented PeerDreams’ prospects for success during a series of meetings between mid-December 2006 and early January 2007.<sup>10</sup> TAC at ¶ 108. According to the TAC, Mr. Fischer falsely represented:

- “That PeerDreams had a marketing plan . . . that called for profitable operations within 18 months in operations targeted to students, charities, pets/animals, travel,

---

<sup>9</sup> True and correct copies of the PeerDreams Agreements are attached to the accompanying Declaration of Mani Kulasooriya (“Kulasooriya Decl.”) as Exs.1-5. The first such agreement (Kulasooriya Decl. Ex. 1) shows that one of the loans was made by Upper Orbit, LLC, a limited liability company owned by Mr. Fischer, not Plaintiff. Thus, Plaintiff has no standing to use that particular loan as a basis for relief.

<sup>10</sup> The TAC also purports to assert claims for relief against Monvia LLC (“Monvia”). The Court dismissed Plaintiff’s claims against Monvia with prejudice in the December Order. ECF No. 241.

1 equipment purchase, small businesses, environmental products and community  
 2 projects ...." (TAC at ¶ 110 (a));

- 3 • "That Koolasuriya had extensive experience with comparable entrepreneurial  
 4 software investments through his previous work at Yahoo Finance...." (*Id.* at ¶  
 110(b));
- 5 • "That the software and website [for PeerDreams] could be up and running within  
 6 12 months...." (*Id.* at ¶ 110(c));
- 7 • "That, based on the funds raised and needed in the next year, PeerDreams would  
 8 be up and running and able [to] extract substantial profit as a fund raising  
 9 platform...." (*Id.* at ¶ 110(d)); and
- 10 • "That the funds raised in the first year would be sufficient to fund the development  
 11 of 'white label' (private label) sites for specific institutions . . . ." (*Id.* at ¶ 110(e)).

12 As discussed in detail below, none of Mr. Fischer's statements are alleged to have been false or  
 13 misleading when made, and none can support a claim for relief against Mr. Fischer or the  
 14 PeerDreams Defendants.<sup>11</sup> *See* Section V.A, *infra*.

### 15 **III. PROCEDURAL BACKGROUND**

16 Plaintiff commenced this action in June 2011. ECF No. 1. She filed a First Amended  
 17 Complaint on December 5, 2011 (ECF No. 58) and a Second Amended Complaint on June 15, 2012  
 18 (the "SAC") (ECF No. 113). The SpeciGen Defendants (except for Brian Campion), PeerDreams  
 19 Defendants and others filed motions to dismiss the SAC in August 2012 (ECF Nos. 125, 127 and  
 20 128), which were granted with leave to amend by order dated March 15, 2013 (the "March Order")  
 (ECF No. 177).

21 In the meantime, Mr. Fischer filed for Chapter 7 bankruptcy protection in the U.S. Bankruptcy  
 22 Court for the District of Minnesota in April 2012 (ECF No. 104), which stayed the present action  
 23 against him. *See generally* 11 U.S.C. § 362(a)(1) (automatic stay provision). Plaintiff commenced an  
 24 adversary proceeding against Mr. Fischer on July 17, 2012 (the "Adversary Proceeding"), thereby  
 25 circumventing the PSLRA's mandatory discovery stay and opening the door to discovery to which

---

26 <sup>11</sup> On December 20, 2013, this Court granted Defendants Monvia LLC ("Monvia"), Mani  
 27 Kulasooriya's and Jorge Fernandes' motions to dismiss Plaintiff's Third Amended Complaint (the  
 28 "TAC"). All of the TAC's causes of action against Monvia were dismissed with prejudice.

1 she would not otherwise be entitled in this Court. As a result of the Adversary Proceeding, Plaintiff  
 2 has been able to conduct extensive discovery, including document discovery and depositions.  
 3 Among other things, Plaintiff has received “25,000 documents” from Mr. Fischer (Transcript of  
 4 December 5, 2012 Oral Argument at 17:10) (ECF No. 174) and taken Mr. Fischer’s deposition (see  
 5 TAC at ¶¶ 45, 61, 92, 111, 115 and 142) (referring to Mr. Fischer’s deposition testimony).<sup>12</sup>

6 Plaintiff filed the TAC on April 25, 2013. ECF No. 180. Although Plaintiff’s amended  
 7 pleading was intended to incorporate the fruits of her discovery in the Adversary Proceeding, the  
 8 TAC still failed to plead the basic elements of any claim for relief against Defendants. Accordingly,  
 9 the SpeciGen Defendants (except for Mr. Campion), PeerDreams Defendants and others filed another  
 10 round of motions to dismiss in May and June 2013 (ECF Nos. 190, 191, 193 and 201), which were  
 11 granted in part and denied in part by order dated December 20, 2013 (ECF No. 241) (the “December  
 12 Order”). The December Order dismissed most of Plaintiff’s claims for relief against the SpeciGen  
 13 Defendants (except for Mr. Campion) and PeerDreams Defendants with prejudice, leaving only  
 14 Plaintiff’s Secondary Liability Claims.<sup>13</sup>

15 Plaintiff’s Secondary Liability Claims against Defendants depend upon the existence of a

---

16 <sup>12</sup> Plaintiff has also received extensive discovery from Jon Sabes and Steven Sabes, including  
 17 tens of thousands of pages of documents and Jon Sabes’ deposition.

18 <sup>13</sup> The Court dismissed the following claims against the SpeciGen Defendants (except for Mr.  
 19 Campion) and the PeerDreams Defendants with prejudice: (a) Plaintiff’s First Claim for Relief (for  
 20 violations of Section 10(b); (b) Plaintiff’s Second Claim for Relief (for violations of Sections 25401  
 21 and 25501); (c) Plaintiff’s Fifth Claim for Relief (for Breach of Fiduciary duty); (d) Plaintiff’s Eighth  
 22 Claim for Relief (for Negligent Misrepresentation); and (e) Plaintiff’s Ninth Claim for Relief (for  
 23 direct violations of Section 25501.5); and (f) Plaintiff’s Tenth Claim for Relief (for Common Law  
 24 Misrepresentation) (together, “Plaintiff’s Primary Liability Claims”). Thus, Plaintiff’s Secondary  
 25 Liability Claims are the only remaining claims against the SpeciGen Defendants (except for Mr.  
 26 Campion) and the PeerDreams Defendants.

27 The Notebookz Defendants and Mr. Campion believe that Plaintiff’s Primary Liability Claims  
 28 against them suffer from all of the same fatal defects described in the Court’s previous orders.  
 Accordingly, the Notebookz Defendants and Mr. Campion respectfully submit that the Court should  
*sua sponte* enter a conforming order dismissing Plaintiff’s Primary Liability Claims against them. If  
 the Court is not inclined to do so, the Notebookz Defendants and Mr. Campion respectfully request  
 leave to file a further motion for judgment on the pleadings, as set forth in the Court’s minute order  
 dated April 10, 2014 (ECF No. 250).

1 primary violation by Mr. Fischer. The Court did not consider the viability of Plaintiff's claims against  
 2 Mr. Fischer in the December Order. Since then, however, the Adversary Proceeding has been  
 3 resolved (ECF Nos. 239 and 240) and the parties agree that the stay has been lifted (ECF No. 248).  
 4 Accordingly, the Court may now consider Plaintiff's claims against Mr. Fischer. As discussed in  
 5 detail below, the TAC fails to allege a primary violation of federal or state securities laws by Mr.  
 6 Fischer. *See* Section V, *infra*. As a result, Plaintiff's Secondary Liability Claims fail to state a claim  
 7 for relief against Defendants.

8 **IV. APPLICABLE LEGAL STANDARDS**

9 Rule 12(c) permits a party to move for judgment on the pleadings "after the pleadings are  
 10 closed – but early enough not to delay trial." Fed. R. Civ. Proc. 12(c). No trial date has been set in  
 11 this case; therefore, the present motion will not delay trial.

12 A motion for judgment on the pleadings pursuant to Rule 12(c) is governed by the same  
 13 standards as a motion to dismiss for failure to state a claim pursuant to Rule 12(b)(6). *See, e.g.*,  
 14 *Chavez v. U.S.*, 683 F.3d 1102, 1108 (9<sup>th</sup> Cir. 2012) ("Analysis under Rule 12(c) is 'substantially  
 15 identical' to analysis under Rule 12(b)(6) because, under both rules, 'a court must determine whether  
 16 the facts alleged in the complaint, taken as true, entitle the plaintiff to a legal remedy'"') (*quoting*  
 17 *Brooks v. Dunlop Mfg. Inc.*, 2011 WL 6140912, \*3 (N.D. Cal. Dec. 9, 2011)). "Judgment on the  
 18 pleadings is appropriate when a plaintiff's complaint fails to meet the pleading standards established  
 19 by the Private Securities Litigation Reform Act of 1995 (PSLRA)." *Plumbers & Pipefitters Local*  
 20 *572 Pension Fund v. Cisco Systems, Inc.*, 411 F.Supp.2d 1172, 1174 (N.D. Cal. 2005).

21 To survive a motion for judgment on the pleadings, a complaint must set forth "'sufficient  
 22 factual matter, accepted as true, to state a claim for relief that is plausible on its face.'" *Harris v.*  
 23 *County of Orange*, 682 F.3d 1126, 1131 (9<sup>th</sup> Cir. 2012) (*quoting Ashcroft v. Iqbal*, 556 U.S. 662, 678  
 24 (2009) (internal quotation marks and citation omitted)); *see also Cafasso, U.S. ex rel. v. General*  
 25 *Dynamics C4 Systems, Inc.*, 637 F.3d 1047, 1054 n. 4 (9<sup>th</sup> Cir. 2011) (*Iqbal* applies to Rule 12(c)  
 26 motions because Rule 12(b)(6) and Rule 12(c) motions are "functionally identical"). "A claim has  
 27 facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable  
 28 inference that the defendant is liable for the misconduct alleged." *Id.* As this Court has explained, "a

1 plaintiff's obligation to provide the grounds of his entitlement to relief 'requires more than labels and  
 2 conclusions, and a formulaic recitation of the elements of a cause of action will not do.'" *In re Bare*  
 3 *Escentuals, Inc. Sec. Litig.*, 745 F.Supp.2d 1052, 165 (N.D. Cal. 2010) (quoting *Bell Atlantic Corp. v.*  
 4 *Twombly*, 550 U.S. 544, 555 (2007)).

5 Where the complaint alleges fraud, plaintiff must also satisfy the heightened pleading  
 6 standards mandated by Rule 9(b). Rule 9(b) requires the plaintiff to state with particularity the  
 7 circumstances constituting fraud, including the "who, what, when, where, and how" of the charged  
 8 misconduct. *Vess v. Ciba Geigy Corp. USA*, 317 F.3d 1097, 1106 (9<sup>th</sup> Cir. 2003). "Under Rule 9(b),  
 9 falsity must be pled with specificity, including an account of the 'time, place, and specific content of  
 10 the false representations as well as the identities of the parties to the misrepresentations.'" Order at 6  
 11 (quoting *Swartz v. KPMG LLP*, 476 F.3d 756, 764 (9<sup>th</sup> Cir. 2007)). "In addition, the plaintiff must do  
 12 more than simply allege the neutral facts necessary to identify the transaction; he must also explain  
 13 why the disputed statement was untrue or misleading at the time it was made." *Id.* Plaintiff's  
 14 allegations against Mr. Fischer do not come close to meeting these standards.

15 **V. ARGUMENT**

16 **A. Plaintiff Fails To Allege A Primary Violation Of Section 10(b)**

17 Section 10(b) of the Exchange Act provides, in part, that it is unlawful "to use or employ in  
 18 connection with the purchase or sale of any security registered on a national securities exchange or  
 19 any security not so registered, any manipulative or deceptive device or contrivance in contravention of  
 20 such rules and regulations as the [SEC] may prescribe." 15 U.S.C. § 78j(b). To state a claim under  
 21 Section 10(b) and Rule 10b-5 thereunder, a plaintiff must allege (1) a misrepresentation or omission,  
 22 (2) of material fact, (3) made with scienter, (4) on which the plaintiff justifiably relied, (5) that  
 23 proximately caused the alleged loss. *Binder v. Gillespie*, 184 F.3d 1059, 1063 (9th Cir. 1999).

24 Plaintiffs have long been required to plead securities fraud with the specificity mandated by  
 25 Rule 9(b). *GlenFed, supra*, 42 F.3d at 1545. In addition, plaintiffs must now satisfy the  
 26 requirements of the PSLRA. As this Court has explained:

27  
 28

Congress established the PSLRA to establish uniform and stringent pleading requirements for securities fraud actions, and to put an end to the practice of pleading “fraud by hindsight.” *See In re Silicon Graphics, Inc.*, 183 F.3d 970, 988 (9<sup>th</sup> Cir. 1999). Under the PSLRA, the complaint must plead both falsity and scienter with particularity. *Zucco Partners, LLC v. Digimarc Corp.*, 552 F.3d 981, 990 (9<sup>th</sup> Cir. 2009). If the complaint does not satisfy the PSLRA’s pleading requirements, the court, upon motion of the defendant, must dismiss the complaint. 15 U.S.C. § 78u-4(b)(3)(A).

*Jackson v. Fischer*, 931 F.Supp.2d 1049, 1059 (N.D. Cal. 2013). As discussed in detail below, Plaintiff fails to plead a Section 10(b) claim against Mr. Fischer with the specificity required by Rule 9(b) and the PSLRA.

## 1. Plaintiff Fails To Allege An Actionable Misstatement By Mr. Fischer

Even before the passage of the PSLRA, the Ninth Circuit required that every security fraud complaint “adequately specify the statements it claims were false or misleading, give particulars as to the respect in which plaintiff contends the statements were fraudulent, state when and where the statements were made, and identify those responsible for the statements.” *GlenFed, supra*, 42 F.3d at 1548. In addition, both the Ninth Circuit and the PSLRA now demand that plaintiffs “specify each statement alleged to have been false or misleading, the reason or reasons why the statement is misleading, and, if an allegation regarding the statement or omission is made on information and belief . . . state with particularity all facts on which that belief is formed.” 15 U.S.C. § 78u-4(b)(1); *see also Zucco Partners, LLC v. Digimarc Corp*, 552 F.3d 981, 991 (9<sup>th</sup> Cir. 2009). The TAC does not satisfy these requirements with respect to any of the Defendant Companies.

**a. Plaintiff Fails To Allege An Actionable Misstatement Regarding SpeciGen**

The TAC alleges that Mr. Fischer orally misrepresented SpeciGen’s product development, partnership and fundraising prospects (TAC at ¶¶ 87 and 89), but does not specify what Mr. Fischer actually said. Instead, Plaintiff “repackages defendants’ actual oral statements in vague and impressionistic terms.” *Wenger v. Lumisys, Inc.*, 2 F.Supp.2d 1231, 1246 (N.D. Cal. 1998). See, e.g., TAC at ¶ 89(a) (alleging that “defendants” falsely represented that “the Series A offering was moving along well”).<sup>14</sup> Courts throughout the Northern District of California have rejected Plaintiff’s

<sup>14</sup> Of course, reasonable investors do not rely on vague statements of corporate optimism like “the

1 “impressionistic approach to pleading fraud,” and this Court should not hesitate to do the same.  
 2 *Wenger*, 2 F.Supp.2d at 1247; and see *Copperstone v. TCSI Corp.*, 1999 WL 33295869, \*9 (N.D.  
 3 Cal. Jan. 19, 1999) (dismissing claims based on alleged oral statements where, as here, “Plaintiffs  
 4 never allege who made the statement [or] what was actually said”).

5 Similarly, Plaintiff alleges that Mr. Fischer failed to disclose a wide range of operational  
 6 issues, including intra-corporate conflicts, pro forma financial projections and fundraising challenges  
 7 (TAC at ¶ 90), but does not identify a single statement, by Mr. Fischer or anyone else, that was  
 8 allegedly false or misleading by reason of a supposed omission. *See generally City of Roseville*  
 9 *Retirement System v. Sterling Financial Corp.*, 963 F.Supp.2d 1092, 1109 (E.D. Wash. 2013) (“when  
 10 a plaintiff relies on an omission of fact as evidence of falsity, the plaintiff cannot simply show that the  
 11 omission was material; instead, the plaintiff must show that the omission actually renders *other*  
 12 statements misleading”) (emphasis original) (*citing In re Rigel Pharm., Inc. Sec. Litig.*, 697 F.3d 869,  
 13 880 n. 8 (9<sup>th</sup> Cir. 2012)). Thus, Plaintiff fails to comply with the PSLRA’s threshold requirement that  
 14 she “specify each statement alleged to have been misleading.” 15 U.S.C. § 78u-4(b)(1).

15 Plaintiff not only fails to specify Mr. Fischer’s alleged misstatements, she also fails to specify  
 16 “the reason or reasons why” any such statements were false or misleading when made. According to  
 17 Plaintiff, Mr. Fischer and/or “defendants” misrepresented SpeciGen’s (1) product development efforts  
 18 (TAC at ¶ 87(a), 87(d) and 89(b)); (2) partnership prospects (*id.* at ¶¶ 87(a), 87(c) and 89(c)); (3)  
 19 patent portfolio (*id.* at ¶ 87(h)); and (4) fundraising efforts (*id.* at ¶¶ 87(b), 87(e), 87(f), 87(g) and  
 20 87(h)). Plaintiff generally alleges that each such statement was false, but offers no facts to support her  
 21 characterization. Instead, Plaintiff relies on a series of generalities and *non sequiturs*. As discussed  
 22 in detail below, these allegations do not come close to satisfying Plaintiff’s pleading obligations under  
 23 Rule 9(b) and the PSLRA. *See generally Falkowski v. Imation Corp.*, 309 F.3d 1123, 1133 (9<sup>th</sup> Cir.  
 24 2002) (“vague claims about what statements were false or misleading [and] how they were false” are  
 25

---

26 Series A offering was moving along well” (TAC at ¶ 89(a)), so Plaintiff’s paraphrased portrayal of the  
 27 Mr. Fischer’s alleged oral statement would not be actionable in any event. *See, e.g., In re VeriFone*  
 28 *Sec. Litig.*, 784 F.Supp. 1471, 1481 (N.D. Cal. 1992) (“professional investors, and most amateur  
 investors as well, know how to devalue the optimism of corporate executives”), *aff’d* 11 F.3d 865 (9<sup>th</sup>  
 Cir. 1993).

1 subject to dismissal); *and see Metzler Investment GmBH v. Corinthian Colleges, Inc.*, 540 F.3d 1049,  
 2 1070 (9<sup>th</sup> Cir. 2008) (“A litany of alleged false statements, unaccompanied by the pleading of specific  
 3 facts indicating why those statements were false, does not meet [the PSLRA] standard”);

4 **(i) Product Development Representations**

5 Plaintiff alleges that Mr. Fischer and/or “defendants” falsely represented that SpeciGen’s  
 6 technology was a “proven concept” (TAC at ¶ 87(a)) which had been “vetted” by Genentech (*id.* at ¶  
 7 89(b)) and “validated” by an unidentified “commercial biotech company” (*id.* at ¶ 87(d)). However,  
 8 Plaintiff does not even explain what these alleged misstatements were supposed to mean, let alone  
 9 why they were false or misleading when made.<sup>15</sup>

10 The Ninth Circuit confronted an equally vague series of alleged misrepresentations in *In re*  
 11 *Vantive Corp. Sec. Litig.*, 283 F.3d 1079 (9<sup>th</sup> Cir. 2002). In *Vantive*, plaintiffs claimed that  
 12 defendants overstated the growth and quality of their sales force. The trial court dismissed the  
 13 complaint and the Ninth Circuit affirmed, explaining that “the complaint leaves unclear what it would  
 14 mean for Vantive to ‘adequately train’ an employee, what ‘sufficient numbers’ of hires would be, or  
 15 what it means for ‘a substantial percentage’ of people to quit.” 283 F.3d at 1086-1087. Similarly, in  
 16 this case, the TAC offers no explanation of the terms “proven concept,” “validated” or “vetted” and  
 17 provides no objective criteria by which the truth or falsity of the alleged misstatements could be  
 18 measured. In the absence of any such details, the TAC fails to establish that the alleged misstatements  
 19 concerning SpeciGen’s product development efforts were false or misleading when made. *See*  
 20 *Vantive*, 283 F.3d at 1086-1087 (complaint inadequate for failing to provide an objective measure  
 21 against which allegedly “false” statements could be compared).

22 **(ii) Partnership Representations**

23 Plaintiff’s claim that Mr. Fischer misrepresented SpeciGen’s partnership prospects is equally

---

24  
 25 <sup>15</sup> Furthermore, though Plaintiff alleges that “Genentech had been approached had been approached  
 26 but shown no interest in partnering with SpeciGen” (TAC at ¶89(b)) and SpeciGen’s “only revenues  
 27 had been primary research grants by government agencies” (*id.* at ¶ 87(d)), these *non sequiturs* do not  
 28 amount to an explanation why any statement was false or misleading. After all, Genentech could  
 have “vetted the company’s technology” (whatever that means) and *then* decided against partnering  
 with SpeciGen. Similarly, a commercial biotech company could have “validated” SpeciGen’s  
 technology (whatever that means) without giving SpeciGen money.

1 flawed. Plaintiff alleges that Mr. Fischer falsely represented that SpeciGen was “in advanced  
 2 discussions with a public company and an established private biotech company about advanced  
 3 research partnerships that would develop preclinical data sufficient to complete clinical trials.” TAC  
 4 at ¶ 89(c). However, Plaintiff does not specify what Mr. Fischer actually said, whether he used the  
 5 terms “advanced discussions” and “advanced research partnerships” and if so, what he meant by  
 6 them. Instead, Plaintiff offers a vague characterization of the alleged misstatement and summarily  
 7 concludes that the statement was false “because no such discussions were underway.” TAC at ¶  
 8 89(c). But these non-specific allegations do not explain anything. Was the alleged oral statement  
 9 false because SpeciGen was not discussing research partnerships with anyone? Because SpeciGen  
 10 was discussing research partnerships, but the discussions were preliminary, not advanced? Because  
 11 SpeciGen was discussing research partnerships, but the research partnerships themselves were not  
 12 advanced? Or were not likely to result in the development of preclinical data sufficient to complete  
 13 clinical trials? Plaintiff does not say. Nor does she attempt to reconcile her allegation that “no such  
 14 discussions were underway” (TAC at ¶89(c)) with her seemingly contradictory allegations that (1)  
 15 some companies, including Genentech, apparently considered research partnerships with SpeciGen at  
 16 some unspecified times (TAC at ¶¶ 87(b) and 89(b)); and (2) SpeciGen ultimately formed a research  
 17 partnership with another company (*id.* at ¶ 89(c)), although it was not as productive as Plaintiff would  
 18 have liked. These inconsistent allegations do not explain why any alleged oral statement was false or  
 19 misleading when made.

20 **(iii) Patent Portfolio Representations**

21 Next, Plaintiff claims that Mr. Fischer falsely represented that “SpeciGen had all of the  
 22 licenses and patents needed to commercially develop its technologies.” TAC at ¶ 87(h). Once again,  
 23 Plaintiff does not specify what Mr. Fischer actually said or why the statement was false or misleading  
 24 when made. Instead, Plaintiff claims that SpeciGen’s licenses “required ongoing royalty payments  
 25 that it could not maintain at the company’s present burn rate.” TAC at ¶ 87(h).

26 Contrary to Plaintiff’s suggestion, the alleged representation that “SpeciGen had all of the  
 27 licenses and patents needed to commercially develop its technologies” does not carry an implied  
 28 representation that all such licenses and patents would be available to SpeciGen for free. Nor does the

1 statement impliedly represent that royalty payments would not be difficult to make, given “the  
 2 company’s present burn rate.” In the absence of greater particularity, Plaintiff has again failed to  
 3 establish that any alleged statement concerning SpeciGen’s patent portfolio was false or misleading  
 4 when made.

5 **(iv) Fundraising Representations**

6 Finally, Plaintiff claims that Mr. Fischer falsely represented that the Series A offering “would  
 7 be fully sufficient to carry the company to its ‘exit strategy’” (TAC at ¶ 87(b)), which “would come  
 8 within 2-3 years” (*id.* at ¶ 87(g)). According to Plaintiff, these representations were false because (1)  
 9 the Series A offering would not be enough to get SpeciGen to preliminary trials (TAC at ¶ 87(b)(a));  
 10 and (2) barring an acquisition or substantial outside investment, “it would take an estimated 12-15  
 11 years for a return on investment” (*id.* at ¶ 87(g)(3)). Put another way, the TAC alleges that Mr.  
 12 Fischer failed to predict how much time and money would be required before Plaintiff would be in a  
 13 position to recoup her investment. However, “the fact that a prediction proves to be wrong in  
 14 hindsight does not render the statement untrue when made.” *In re Syntex Corp. Sec. Litig.*, 95 F.3d  
 15 922, 929 (9<sup>th</sup> Cir. 1996). Furthermore, to the extent that the TAC specifies the challenged statements  
 16 at all, they are forward-looking. *See generally No. 84 Employer-Teamster Joint Council Pension*  
 17 *Trust Fund v. Am. W. Holding Corp.*, 320 F.3d 920, 936 (9<sup>th</sup> Cir. 2003) (A forward-looking statement  
 18 includes any statement regarding “plans and objectives of management for future operations” and “the  
 19 assumptions ‘underlying or related to’ any of these issues”). As such, the alleged misstatements could  
 20 not be actionable unless (1) they were not actually believed by the speaker; (2) there was no  
 21 reasonable basis for the belief; or (3) the speaker was aware of undisclosed facts tending to seriously  
 22 undermine the statement’s accuracy. *See, e.g., In re Oracle Corp. Sec. Litig.*, 627 F.3d 376, 388 (9<sup>th</sup>  
 23 Cir. 2010). As discussed in detail below, the TAC does not support an inference that Mr. Fischer  
 24 acted with deliberate recklessness, much less actual knowledge of falsity. *See* Section V.A.2, *infra*.

25 **b. Plaintiff Fails To Allege An Actionable Misstatement Regarding**  
 26 **Notebookz**

27 Next, Plaintiff claims that Mr. Fischer made false and misleading statements about  
 28 “Notebookz/iLeonardo.” TAC at ¶¶ 96-98. Once again, Plaintiff “repackages” Mr. Fischer’s

1 alleged oral statements in “vague and impressionistic terms,” leaving Defendants to guess what  
2 Mr. Fischer actually said. *Wenger, supra*, 2 F.Supp.2d at 1247. To make matters worse, Plaintiff  
3 repeatedly refers to Notebookz and iLeonardo as “the company,” leaving Defendants to guess  
4 which company Mr. Fischer allegedly misrepresented. Such vague allegations have never been  
5 enough to satisfy the heightened pleading standards mandated by Rule 9(b) and PSLRA.  
6 Furthermore, Plaintiff’s allegations suffer from a number of additional defects, each of which  
7 independently compel dismissal.

**(i) Plaintiff Fails To Allege That Mr. Fischer's Forward-Looking Statements Were Made With Actual Knowledge Of Falsity**

10 Plaintiff alleges that Mr. Fischer and/or Mr. Rosen falsely represented that “they expected  
11 Google to acquire the company.” TAC at ¶ 97(b); *see also id.* at ¶ 96 (alleging that “[Rosen] or  
12 Fischer specifically mentioned the likelihood that Google would be a likely acquirer in the near to  
13 intermediate future”). Plaintiff further alleges that Mr. Fischer and/or Mr. Rosen falsely  
14 represented:

that the company had, independently of [Plaintiff's] investment, raised sufficient capital to produce and market its product, when in fact it had insufficient capital and would need substantial further investment to complete a finished product and bring it to commercialization.

18 TAC at ¶ 97(a). As usual, Plaintiff does not identify *which* speaker allegedly said *what* about  
19 *which* company. But these pleading failures cannot disguise the fact that Mr. Fischer's alleged  
20 misstatements are fundamentally forward-looking.

21 As previously discussed, a “forward-looking statement” includes “any statement regarding  
22 (1) financial projections, (2) plans and objectives of management for future operations, (3) future  
23 economic performance, or (4) the assumptions ‘underlying or related to’ any of these issues.” *No.*  
24 *84 Employer-Teamster*, 320 F.3d at 936 (quoting 15 U.S.C. § 78u-5(i); *see* Section \_\_, *supra*). By  
25 definition, Mr. Fischer’s alleged representation that he “expected Google to acquire the company”  
26 constitutes a statement of “management’s plans and objectives for future operations.” 15 U.S.C. §  
27 78u-5(i)(1)(C). Similarly, Mr. Fischer’s alleged representation that “the company” had  
28 “sufficient capital to produce and market its product” constitutes a statement regarding “the

1 company's" financial projections and management's assumptions "underlying or related to" such  
 2 projections. 15 U.S.C. § 78u-5(i).

3 "To show that forward-looking statements are false 'plaintiffs must prove that [they] were  
 4 made with 'actual knowledge' that they were false or misleading.'" *In re American Apparel, Inc.*  
 5 *Shareholder Litig.*, 2013 WL 174199, \*27 (C.D. Cal. Jan. 16, 2013) (quoting *Silicon Graphics*,  
 6 183 F.3d at 993 (Browning, J., concurring in part and dissenting in part) and 15 U.S.C. §§ 78u-  
 7 5(c)(1)(B), 77z-2(c)(1)(B)); *see also In re Northpoint Communications Grp., Inc. Sec. Litig.*, 184  
 8 F.Supp.2d 991, 997 (N.D. Cal. 2001) (providing examples of sufficient factual allegations of  
 9 scienter such as "'contemporaneous receipt of a report with information directly at odds with an  
 10 alleged misrepresentation, . . . and statements by witnesses that they told the actor the true facts  
 11 before the false statement was made . . .'). Despite extensive discovery, Plaintiff does not allege  
 12 any facts establishing that Mr. Fischer's forward-looking statements were made with actual  
 13 knowledge of falsity. *See* Section V.A.2, *infra*. Thus, Plaintiff fails to state a claim for relief  
 14 based on any alleged misstatement regarding an acquisition by Google or the amount of capital  
 15 that would be needed to "complete a finished product and bring it to commercialization."

16 (ii) **Plaintiff Fails To Allege That She Reasonably  
 17 Relied On Any Alleged Misstatement Regarding  
 Her Own Due Diligence Investigation**

18 Next, Plaintiff claims that Mr. Fischer falsely represented that (1) "the company had  
 19 'discussed with [Plaintiff] the company's business, management, financial affairs' and the details  
 20 of its offering" (TAC at ¶ 97(b)); (2) "the company had given [Plaintiff] the opportunity to review  
 21 the company's facilities" (*id.* at ¶ 97(c)); and (3) "the company had given [Plaintiff] the  
 22 opportunity to review all of the terms and conditions of its securities offering" (*id.* at ¶ 97(d)).  
 23 None of these allegations can support a claim for relief against Mr. Fischer or anyone else.

24 "Reliance by the plaintiff upon the defendant's deceptive acts is an essential element of  
 25 the § 10(b) private cause of action." *Stoneridge Inv. Partners, LLC v. Scientific-Atlanta*, 552 U.S.  
 26 148, 159 (2008) (requirement of reliance "ensures that, for liability to arise, the 'requisite causal  
 27 connection between a defendant's misrepresentation and a plaintiff's injury' exists as a predicate  
 28 for liability") (quoting *Basic, Inc. v. Levinson*, 485 U.S. 224, 243 (1988)). The Ninth Circuit has

1 long recognized that plaintiffs cannot plausibly allege reliance where, as here, they already  
2 possess sufficient information to call defendants' alleged misrepresentations into question. *See*  
3 *Atari Corp. v. Ernst & Whinney*, 981 F.2d 1025, 1030 (9th Cir. 1992) ("If the investor already  
4 possesses information sufficient to call the representations into question, he cannot claim later  
5 that he relied on or was deceived by the lie."). Likewise, in the present case, Plaintiff cannot  
6 credibly claim to have relied on alleged misrepresentations regarding her own due diligence  
7 investigation (e.g., whether or not she was given an opportunity to tour the company's facilities or  
8 review the terms and conditions of its securities offering) when "the truth" was already in her  
9 possession. Thus, Plaintiff fails to state a claim for relief based on any alleged misrepresentation  
10 regarding her own due diligence investigation.

(iii) Plaintiff Fails To Allege An Actionable Misstatement Based On “The Company’s” Promise To Provide Her With Periodic Financial Reports

Finally, Plaintiff claims that Mr. Fischer gave her an “Investors Rights Agreement” which falsely promised that “the company” would make certain financial information available to her at the end of each fiscal year. TAC at ¶ 99. Although the Ninth Circuit does not appear to have addressed the issue, the Second Circuit has held that:

23 *Mills v. Polar Molecular Corp.*, 12 F.3d 1170, 1176 (2<sup>nd</sup> Cir. 1993) (declining to infer fraudulent  
24 intent from the mere fact that defendant failed to perform as promised); *see also ATSI Commc'n,  
25 Inc. v. Shaar Fund, Ltd.*, 493 F.3d 87, 105 (2<sup>nd</sup> Cir. 2007) (“While the failure to carry out a  
26 promise in connection with a securities transaction might constitute breach of contract, it does not  
27 constitute fraud unless, when the promise was made, the defendant secretly intended not to

1 perform or knew that he could not perform"). Plaintiff does not allege any facts – let alone  
 2 particularized facts – suggesting that Mr. Fischer or anyone else connected with “the company”  
 3 harbored a secret intention not to perform or knew that they could not perform. Thus, Plaintiff  
 4 fails to state a claim for relief based on any alleged misstatement in the Investor’s Rights  
 5 Agreement or any other statement regarding Notebookz or iLeonardo.

6 **c. Plaintiff Fails To Allege An Actionable Misstatement Regarding  
 7 PeerDreams**

8 Finally, Plaintiff alleges that Mr. Fischer falsely represented that (1) PeerDreams had a  
 9 marketing plan that called for profitable operations within 18 months (TAC at ¶ 110(a)); (2) one  
 10 of PeerDreams’ founding directors, Mr. Kulasooriya, had extensive experience with comparable  
 11 investments (*id.* at ¶ 110(b)); (3) PeerDreams’ software and website could be up and running  
 12 within 12 months (*id.* at ¶ 110(c)); (4) PeerDreams would be profitable as a fundraising platform  
 13 within a year (*id.* at ¶ 110(d)); and (5) PeerDreams had enough money to “fund the development  
 14 of ‘white label’ (private label) sites for specific institutions” (*id.* at ¶ 110(e)). None of these  
 15 allegations establish a primary violation by Mr. Fischer.

16 “The PSLRA has exacting requirements for pleading ‘falsity.’” *Metzler Inv. GMBH v.*  
 17 *Corinthian Colleges, Inc.*, 540 F.3d 1049, 1070 (9<sup>th</sup> Cir. 2008). A plaintiff must provide “specific  
 18 references to specific facts demonstrating that the statements at issue were false or misleading  
 19 when made.” *Wenger*, 2 F.Supp.2d at 1250. “Moreover, the complaint must allege that the ‘true  
 20 facts’ arose *prior* to the allegedly misleading statement.” *In re Splash Tech. Holdings, Inc. Sec.*  
 21 *Litig.*, 160 F.Sup.2d 1059, 1072 (N.D. Cal. 2001). As the Ninth Circuit has explained, “[t]he  
 22 most direct way to show both that a statement was false when made and that the party making the  
 23 statement knew that it was false is via contemporaneous reports or data, available to the party,  
 24 which contradict the statement.” *Nursing Home Pension Fund, Local 144 v. Oracle Corp.*, 380  
 25 F.3d 1226, 1230 (9<sup>th</sup> Cir. 2004); *see also Berson v. Applied Signal Tech., Inc.*, 527 F.3d 982, 989  
 26 (9<sup>th</sup> Cir. 2008) (the PSLRA requires “particular allegations which strongly imply Defendants’  
 27 *contemporaneous* knowledge that the statement was false when made”) (emphasis original).

28 The TAC makes no attempt to plead contemporaneous facts establishing that any alleged

1 misstatement regarding PeerDreams was false or misleading when made. Plaintiff does not  
 2 specify what Mr. Fischer allegedly said about PeerDreams' marketing plan or plead facts  
 3 demonstrating that any such statement was knowingly false or misleading when made. Nor does  
 4 Plaintiff plead facts establishing that Mr. Kulasooriya lacked "experience with comparable  
 5 entrepreneurial software investments." To the contrary, the TAC concedes that Mr. Kulasooriya  
 6 was experienced, but concludes that his experience was "of no relevance to a modest startup."  
 7 TAC at ¶ 110(b). However, Plaintiff's difference of opinion does not establish fraud, particularly  
 8 when Plaintiff could have easily compared Yahoo! and PeerDreams for herself, and drawn her  
 9 own conclusion as to whether Mr. Kulasooriya's experience was relevant.

10 Plaintiff's remaining allegations are classic "fraud by hindsight." *Silicon Graphics*, 183  
 11 F.3d at 988 ("fraud by hindsight" is not actionable under the federal securities laws); *see also*  
 12 *Jackson v. Fischer*, 931 F.Supp.2d at 1059 (noting that Congress enacted the PSLRA to "put an  
 13 end to the practice of pleading 'fraud by hindsight'"). For example, Plaintiff alleges that Mr.  
 14 Fischer falsely represented that PeerDreams' website would be operational within a year, when  
 15 "[he] knew it would take more than 18 months to develop it and as long to come up with a real  
 16 marketing plan." TAC at ¶ 110(c). Similarly, Plaintiff alleges that Mr. Fischer falsely predicted  
 17 that PeerDreams had enough "the funds raised in the first year would be sufficient to fund the  
 18 development of 'white label' (private label) sites for specific institutions, when in fact the amount  
 19 planned to be raised was insufficient to fund the development of a single white label site." *Id.* at  
 20 ¶ 110(e). However, Mr. Fischer's lack of clairvoyance does not constitute securities fraud. *In re*  
 21 *PetSmart*, 61 F. Supp. 2d 982, 992 (D. Ariz. 1999) ("defendants' lack of clairvoyance simply  
 22 does not constitute securities fraud") (*citing Acito v. IMCERA Group, Inc.*, 47 F.3d 47, 53 (2d Cir.  
 23 1995)); *see also In re Northpoint Communications Group, Inc. Sec. Litig.*, 184 F. Supp. 2d 991,  
 24 1004 (N.D. Cal. 2001) (management's "lack of foresight" is not "actionable as securities fraud").  
 25 "Alleging that certain predictions proved incorrect is not the same as alleging with particularity  
 26 facts that show the initial prediction was a falsehood." *Browning v. Amyris, Inc.*, 2014 WL  
 27 1285175, \*11 (N.D. Cal. Mar. 24, 2014); *see also In re Syntex Corp. Sec. Litig.*, 95 F.3d 922, 934  
 28 (9<sup>th</sup> Cir. 1996) ("Because Defendants' predictions proved to be wrong in hindsight does not

1 render the statements untrue when made"). Accordingly, "plaintiffs must allege with particularity  
 2 facts that show the initial prediction was 'a falsehood.'" *In re American Apparel, Inc.*  
 3 *Shareholder Litig.*, 2013 WL 174119, \*27 (C.D. Cal. Jan. 16, 2013) (*quoting Kane v. Madge*  
 4 *Networks N.V.*, 2000 WL 33208116, \*6 (N.D. Cal. May 26, 2000)). The TAC does not allege any  
 5 such facts. As a result, the TAC fails to show that any alleged misstatement regarding  
 6 PeerDreams was false or misleading when made.

7 **2. Plaintiff Fails To Allege Facts Raising An Inference That Mr. Fischer  
 8 Acted With Scienter**

9 To adequately plead scienter under the PSLRA, the complaint must "state with particularity  
 10 facts giving rise to a strong inference that the defendant acted with the required state of mind." 15  
 11 U.S.C. § 78u-4(b)(2). In the Ninth Circuit, the required state of mind is "deliberate or conscious  
 12 recklessness." *In re Silicon Graphics, Inc. Sec. Litig.*, 183 F.3d 970, 988 (9<sup>th</sup> Cir. 1999). To qualify  
 13 as "strong," the Supreme Court has held, "an inference of scienter must be more than merely plausible  
 14 or reasonable – it must be cogent and at least as compelling as any opposing inference of  
 15 nonfraudulent intent." *Tellabs, Inc. v. Makor Issues & Rights, Ltd.*, 551 U.S. 308, 127 S.Ct. 2499,  
 16 2504-2505, 168 L.2d 179 (2007). The Supreme Court has further instructed that, in determining  
 17 whether scienter has been sufficiently pled, a court must review plaintiff's allegations "holistically."  
 18 See *In re VeriFone Holdings, Inc. Sec. Litig.*, 704 F.3d 694, 702 (9<sup>th</sup> Cir. 2012) (*citing Matrixx*  
 19 *Initiatives, Inc. v. Siracusano*, \_\_\_\_ U.S. \_\_\_, \_\_\_, 131 S.Ct. 1309, 1324 (2011)). In this case, none of  
 20 Plaintiff's allegations are cogent or compelling enough to raise a strong inference of scienter, even  
 21 when considered holistically.

22 Remarkably, though Mr. Fischer plays a starring role in the alleged fraud, Plaintiff does not  
 23 even attempt to plead facts demonstrating what Mr. Fischer knew or when he knew it. Despite  
 24 extensive discovery, the TAC does not identify a single email, internal report or other  
 25 contemporaneous document suggesting that any alleged misstatement was knowingly false when  
 26 made. Instead, Plaintiff generally alleges that all defendants, including Mr. Fischer, were "aware"  
 27 that the Defendant Companies (1) needed funding to survive (TAC at ¶¶ 131(a), (c) and (d)); and (2)  
 28 faced significant product development challenges (*id.* at ¶¶ 87(b) and (d)). These generic allegations

1 could be applied to virtually any start-up company. Indeed, the TAC purports to apply the same  
 2 allegations indiscriminately to “all of the ’34 Act defendants” in this action (a group that originally  
 3 included five individual defendants and five separate entities). TAC at p. 33.

4 At best, the TAC describes “routine corporate objectives,” such as the desire to obtain  
 5 financing and develop new products. *In re Rigel Pharmaceuticals, Inc. Sec. Litig.*, 697 F.3d 869, 884  
 6 (9<sup>th</sup> Cir. 2012) (“allegations of routine corporate objectives such as the desire to obtain good financing  
 7 and expand are not, without more, sufficient to allege scienter; to hold otherwise would support a  
 8 finding of scienter for any company that seeks to enhance its business prospects”). However, the  
 9 Ninth Circuit and Northern District of California have consistently rejected attempts to premise a  
 10 strong inference of scienter on such allegations. *See, e.g., Rigel, supra*, 697 F.3d at 884; *see also*  
 11 *Verona Partners, LLC v. Tenet Capital Partners Convertible Opportunities Fund, L.P.*, 2006 WL  
 12 2669035, \*12 (N.D. Cal., Sept. 18, 2006) (“Generalized assertions of financial motive, without more,  
 13 are insufficient to meet the heightened pleading requirement of the PSLRA”). Applying these  
 14 authorities, the Court should likewise reject Plaintiff’s boilerplate allegations, which are not even  
 15 specific to Mr. Fischer, and do not “state with particularity facts giving rise to a strong inference that  
 16 the defendant acted with the required state of mind.” 15 U.S.C. § 78u-4(b)(2). *See, e.g., In re Vantive*  
 17 *Corp. Sec. Litig.*, 283 F.3d 1079, 1085 (9<sup>th</sup> Cir. 2002) (affirming dismissal of Section 10(b) claims  
 18 where “the bulk of the alleged adverse facts are generic, subjective, difficult to prove or refute, and  
 19 could be alleged against almost any company that has experienced a drop in sales revenue”).

20 **B. Plaintiff Fails To Allege A Primary Violation Of Sections 25401 and 25501**

21 Next, Plaintiff argues that Mr. Fischer’s alleged violations of Section 10(b) constitute  
 22 violations of Sections 25401 and 25501. *See* TAC at ¶¶ 134-135 (incorporating Section 10(b)  
 23 allegations by reference). Plaintiff fails to allege a primary violation of Sections 25401 and 25501.

24 Section 25401 provides that:

25  
 26  
 27  
 28

1 It is unlawful for any person to offer or sell a security in this state or  
 2 buy or offer to buy a security in this state by means of any written or  
 3 oral communication which includes an untrue statement of a material  
 4 fact or omits to state a material fact necessary in order to make the  
 statements made, in the light of the circumstances under which they  
 were made, not misleading.

5 Cal. Corp. C. § 25401. Section 25501 provides, in pertinent part, that:

6 Any person who violates Section 25401 shall be liable to the person  
 7 who purchases a security from him or sells a security to him . . . unless  
 8 the defendant proves that the plaintiff knew the facts concerning the  
 untruth or omission or that the defendant exercised reasonable care  
 and did not know . . . of the untruth or omission.

9 Cal. Corp. C. § 25501. Plaintiff's attempt to state a claim for relief under Sections 25401 and 25501  
 10 fails for two reasons. First, Plaintiff fails to allege that Mr. Fischer made a material misstatement  
 11 regarding any of the Defendant Companies.<sup>16</sup> *See* Section V.A.1, *supra*. Second, Plaintiff fails to  
 12 allege privity with Mr. Fischer.

13 “Sections 25401 and 25501 impose liability only on the actual seller of the security.” *Jackson*  
 14 *v. Fischer, supra*, 931 F.Supp.2d at 1063 (*citing Apollo Capital Fund LLC v. Roth Capital Partners,*  
 15 *LLC*, 158 Cal.App.4<sup>th</sup> 226, 253-254 (2007)); *see also Apollo, supra*, 158 Cal.App.4<sup>th</sup> at 254 (“liability  
 16 under section 25501 attaches only to the actual seller of securities”). Plaintiff does not – and cannot –  
 17 allege that she purchased securities from Mr. Fischer, as opposed to the Defendant Companies. *See*  
 18 SpeciGen Agreement (Fischer Decl. Ex. 1); PeerDreams Agreements (Kulasooriya Decl. Exs. 1-5)  
 19 and Notebookz Agreement (Rosen Decl. Ex. 1). Accordingly, Plaintiff fails to allege a primary  
 20 violation of Sections 25401 and 25501 by Mr. Fischer.

21 **C. Plaintiff Fails To Allege A Primary Violation Of Section 25501.5**

22 Finally, the TAC alleges that Mr. Fischer violated Section 25501.5, which makes it “unlawful  
 23 for a person to sell securities to or through an unlicensed broker-dealer.” *Id.* at ¶ 192. Plaintiff's  
 24 theory fails for two reasons: (1) Plaintiff does not – and cannot – allege that she purchased securities  
 25 from Mr. Fischer; and (2) Plaintiff's Section 25501.5 claim is time-barred.

26  
 27 \_\_\_\_\_  
 28 <sup>16</sup>“Section 25401 does not apply to simple nondisclosure.” *Bowden v. Robinson*, 67  
 Cal.App.3d 705, 717 (1977).

1                   **1. Plaintiff's Section 25501.5 Claims Fail Because She Cannot Allege That**  
 2                   **She Purchased Securities From Mr. Fischer**

3                   Section 25501.5, entitled "Action for rescission or damages," provides in pertinent part:

4                   (a)(1) A person who *purchases a security from or sells a security to*  
 5                   a broker-dealer that is required to be licensed and has not, at the time  
 6                   of the sale or purchase, applied for and secured from the commissioner  
 7                   a certificate under Part 3 (commencing with Section 25200), that is in  
 8                   effect at the time of the sale or purchase authorizing that broker-dealer  
 9                   to act in that capacity, may bring an action for rescission of the sale or  
 10                  purchase or, if the plaintiff or the defendant no longer owns the  
 11                  security, for damages.

12                  Cal. Corp. C. § 25501.5 (a)(1) (emphasis added). By its terms, Section 25501.5 establishes a private  
 13                  right of action in favor of a person who purchases a security *from* an unlicensed broker-dealer. *Id.*

14                  The California courts have yet to address Section 25501.5's requirements in a published  
 15                  opinion. *But see Alpinieri v. TGG Management Company*, 2014 WL 1761327, \*7 (Cal.App. 4 Dist.  
 16                  May 5, 2014) (concluding that the phrase "purchases a security from" demonstrates an intent to limit  
 17                  Section 25501.5's civil remedy "only to a person who transacts directly with an unlicensed broker-  
 18                  dealer, that is, who is in privity with an unlicensed broker-dealer . . ."). However, the California  
 19                  Supreme Court has interpreted the phrase "purchases a security from," as used in Section 25501 of the  
 20                  California Corporate Securities Law of 1968, Cal. Corp. Code §§ 25500, *et seq.*, to require privity of  
 21                  contract. *See Mirkin v. Wasserman*, 5 Cal.4<sup>th</sup> 1082, 1104 (1993) (concluding that the phrase  
 22                  "purchases a security from" requires privity of contract); *see also Apollo Capital Fund, LLC v. Roth*  
 23                  *Capital Partners, LLC*, 158 Cal.App.4<sup>th</sup> 226, 253 (2007) ("Section 25501 on its face requires privity  
 24                  between the plaintiff and the defendant"); *and Employers Ins. of Wausau v. Musick, Peeler, &*  
 25                  *Garrett*, 871 F.Supp. 381, 387-388 (S.D. Cal. 1994) (Section 25501 "requires privity between the  
 26                  seller of a secured instrument and a purchaser" and liability "is limited to actual sellers"). "The  
 27                  Legislature is deemed to be aware of existing laws and judicial decisions construing the same statute  
 28                  in effect at the time legislation is enacted, and to have enacted and amended statutes "in light of such  
 decisions as have a direct bearing upon them.'" *Viking Pools, Inc. v. Maloney*, 48 Cal.3d 602, 609  
 (1989). Thus, the Legislature can be presumed to have known that the phrase "purchases a security  
 from" would be construed to require privity of contract when Section 25501.5 was enacted in 2004.

1      *Alpinieri, supra*, 2014 WL 1761327, \*7 (“We conclude that the Legislature in 2004 necessarily  
 2      understood that courts would interpret a civil liability provision under the Act containing the  
 3      “purchases a security from” language as requiring privity of contract as a prerequisite to such  
 4      liability”).

5      Plaintiff claims that Mr. Fischer was an unlicensed broker-dealer, but does not – and cannot –  
 6      allege that she purchased securities from him. To the contrary, the judicially noticeable Agreements  
 7      confirm that she purchased convertible promissory notes and preferred stock from the Defendant  
 8      Companies, and not Mr. Fischer.<sup>17</sup> *See* SpeciGen Agreement at p. 1 (reciting that “each Investor  
 9      desires to purchase, and the Company desires to sell a convertible promissory note in the principal  
 10     amount set forth opposite such Investor’s name”) (Fischer Decl. Ex. 1); *see also* PeerDreams  
 11     Agreement at p. 1 (reciting that “the Company agrees to issue and sell [promissory notes] to each of  
 12     the Investors”) (Kulasooriya Decl. Ex. 2); *and see* Notebookz Agreement at p. 1 (reciting that “THIS  
 13     SERIES A PREFERRED STOCK PURCHASE AGREEMENT” is made between Notebookz, on  
 14     the one hand, and “the investors listed on Exhibit A,” on the other) (Rosen Decl. Ex. 1). As a result,  
 15     Plaintiff does not – and cannot – allege privity of contract with Mr. Fischer, an essential predicate to  
 16     any direct claim for relief under Section 25501.5.

17      **2. Plaintiff’s Section 25501.5 Claim Is Time-Barred**

18      Even assuming *arguendo* that Plaintiff could allege privity of contract (which she cannot), her  
 19      attempt to state a claim for relief under Section 25501.5 would still be time-barred. The applicable  
 20     statute of limitations for claims arising under Section 25501.5 is either (a) Corporations Code Section  
 21     25506, which provide for a two-year statute of limitations from the date of discovery (Cal. Corp. C. §  
 22     25506(b)); or (b) California Civil Code Section 338(a), which provides for a three-statute of  
 23     limitations for claims created by statute. *Jackson v. Fischer, supra*, 931 F.Supp.2d at 1066. Plaintiff  
 24     has previously acknowledged that the applicable statute of limitations is two years from the date of

---

25  
 26      <sup>17</sup> Under California Corporations Code Section 25004, the term “broker-dealer” means “any person  
 27      engaged in the business of effecting transactions in securities in this state for the account of others or  
 28      for his own account.” Cal. Corp. C. § 25004. Section 25004 specifically excludes “any other issuer”  
 from the statutory definition of a “broker-dealer.” Cal. Corp. C. § 25004 (a). Therefore, the  
 Defendant Companies cannot be considered “broker-dealers” within the meaning of Section 25004.

1 discovery. *Id.*

2 As a matter of California law, Section 25506(b)'s two year statute of limitations is triggered  
 3 by inquiry notice, not actual knowledge. *Deveny v. Entropin, Inc.*, 139 Cal.App.4<sup>th</sup> 408, 423 and 428  
 4 (2006) ("Inquiry notice – often called 'storm warnings' in the securities context – gives rise to a duty  
 5 of inquiry 'when the circumstances would suggest to an investor of ordinary intelligence the  
 6 probability that she has been defrauded'); *Kramas v. Security Gas & Oil, Inc.*, 672 F.2d 766, 770-771  
 7 (9<sup>th</sup> Cir. 1982) (Section 25506 begins to run "when the plaintiff discovers the facts constituting the  
 8 violation or in the exercise of reasonable diligence should have discovered them").

9 Plaintiff alleges that she "became concerned" about a \$1 million "trading account" with Mr.  
 10 Fischer "[i]n or about summer 2008." TAC at ¶ 63. Thus, Plaintiff's own allegations confirm that  
 11 there were "storm warnings" giving rise to a duty to inquire as early as "summer 2008," three years  
 12 before Plaintiff filed her initial complaint. Accordingly, Plaintiff's Section 25501.5 claim is time-  
 13 barred unless the statute of limitations is tolled for some reason.

14 Under California law, the statute of limitations can be tolled by the discovery rule, which  
 15 delays the accrual of the date of a cause of action until plaintiff is aware of the injury. *Hopkins v.*  
 16 *Dow Corning Corp.*, 33 F.3d 1116, 1120 (9<sup>th</sup> Cir. 1994). "Where a plaintiff relies on the discovery  
 17 rule, the plaintiff "must specifically plead facts to show (1) the time and manner of discovery and (2)  
 18 the inability to have made earlier discovery despite reasonable diligence." *Micrel, Inc. v. Monolithic*  
 19 *Power Systems, Inc.*, 2005 WL 6426678, \*3 (N.D. Cal. Dec. 9, 2005) (emphasis added). Despite  
 20 multiple opportunities, Plaintiff has never alleged facts showing when she discovered that Mr. Fischer  
 21 was allegedly unlicensed and why she could not have discovered the violation earlier. These pleading  
 22 failures are hardly surprising, considering that such information is "easy to get" and can usually be  
 23 found with "one phone call or web search." U.S. Securities & Exchange Comm'n, Protect Your  
 24 Money: Check Out Brokers and Investment Advisers (Herrera Decl. Ex. B). Under the  
 25 circumstances, Plaintiff's failure to plead facts supporting the application of the discovery rule can  
 26 only be viewed as a concession that there are no such facts. Accordingly, Plaintiff's claim for  
 27 violations of Section 25501.5 is barred by the statute of limitations.

28

1       **VI. CONCLUSION**

2           For all of the foregoing reasons, Defendants respectfully submit that the TAC fails to allege a  
3 primary violation of federal or state securities laws by Mr. Fischer and cannot be amended to do so.  
4 Because Plaintiff's Secondary Liability Claims against Defendants depend on the existence of a  
5 primary violation by Mr. Fischer, and because Plaintiff fails to allege any such violation, Defendants  
6 respectfully submit that Plaintiff's Secondary Liability Claims should be dismissed without further  
7 leave to amend. In addition, the Notebookz Defendants and Mr. Campion respectfully submit that the  
8 Court should *sua sponte* enter a conforming order dismissing Plaintiff's Primary Liability Claims  
9 against them.

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

1 Dated: June 9, 2014

STEIN & LUBIN LLP

3 By: /s/ Tanya Herrera

4 Tanya Herrera  
5 Attorneys for Defendants  
6 Jon Sabes, Steven Sabes and Marvin Siegel

7 Dated: June 9, 2014

8 CLAASSEN, A Professional Corporation

9 By: /s/ John S. Claassen

10 John S. Claassen  
11 Attorneys for Defendants  
12 Brian Campion, NotebookZ, Inc. and Joshua Rosen

13 Dated: June 9, 2014

14 THE LAW OFFICES OF TOM CHIA-KAI WANG

15 By: /s/ Tom Chia-Kai Wang

16 Tom Chia-Kai Wang  
17 Attorneys for Defendant  
18 Mani Kulasooryia

19 Dated: June 9, 2014

20 By: /s/ Mary C. Garfein

21 Mary C. Garfein  
22 Attorneys for Defendant  
23 Jorge Fernandes

24 Dated: June 9, 2014

25 FOX ROTHSCHILD LLP

26 By: /s/ Curtis E. Smolar

27 Curtis E. Smolar  
28 Attorneys for Defendant  
Steve Waterhouse